The triple combination of trastuzumab, pertuzumab and docetaxel was feasible and effective for HER2-mutated pretreated advanced NSCLC patients in a phase II study, with trastuzumab and pertuzumab being the repositionable drugs predicted in our study [58]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.